Longevity Health Holdings, Inc. XAGE

PMGC Holdings (ELAB) secured a five-year royalty stream from Elevai Skincare sale via executed payment agreement with Longevity Health Holdings (XAGE). Royalty payment agreement creates ongoing financial obligation for Longevity Health Holdings affecting its cash flows and performance.

Longevity Health Holdings, Inc. (XAGE) and Innovaccer announce Enterprise AI Center of Excellence after achieving $1M cost savings. AI Center of Excellence launch with Innovaccer after $1M savings represents major strategic tech advancement boosting efficiency and market position.

Longevity Health Holdings, Inc. (XAGE) closed a strategic investment and appointed Ram Ajjarapu as Chairman and CEO to drive acquisition-focused growth. Strategic investment closure and new Chairman-CEO appointment signal major shift toward acquisitions, significantly boosting growth trajectory and investor sentiment.

Longevity Health Holdings, Inc. (XAGE) has achieved top ratings in the Centers for Medicare & Medicaid Services (CMS) Star Quality Measures, reflecting its commitment to excellence in member care. This recognition highlights the company's focus on providing high-quality healthcare services and improving patient outcomes, positioning it favorably in the competitive healthcare market. Achieving top ratings in CMS Star Quality Measures is likely to significantly enhance the company's reputation and operational performance in the healthcare sector.

Longevity Health Holdings, Inc. (XAGE) has been identified as one of the top midday gainers in the stock market, reflecting a notable increase in its share price. This surge may indicate positive investor sentiment or market interest in the company's operations and future prospects. The rise in stock value could be attributed to various factors, including potential developments in the company's business strategy or market positioning. The increase in stock price suggests a moderately noticeable influence on market sentiment and investor interest.

Longevity Health Holdings, Inc. (Nasdaq: XAGE) announced a merger with THPlasma, a plasma collection company, in an all-stock transaction, while terminating its previous agreement with 20/20 BioLabs. The merger is expected to close in Q4 2025 and will allow Longevity to continue trading under the symbol 'XAGE.' THPlasma, valued at $59 million plus a $20 million earnout, is projected to significantly increase revenue and profitability in the coming years. The merger has been unanimously approved by both companies' boards and aims to enhance shareholder value and growth opportunities. The merger with THPlasma represents a significant strategic move that could enhance Longevity's market position and financial performance.

Longevity Health Holdings, Inc. (XAGE) has sold 479,621 shares of common stock at an average price of $4.08 per share, generating approximately $1.96 million in gross proceeds. This financing extends the company's cash runway into Q1 FY26, assuming no growth beyond pro forma consolidated FY24 sales and excluding the planned 20/20 merger. The financing extends the company's cash runway, which may moderately influence its financial stability and operational capacity.

Longevity Health Holdings, Inc. (Nasdaq: XAGE) announced the successful sale of 479,621 shares at an average price of $4.08 per share through its at-the-market equity offering, generating approximately $1.96 million in gross proceeds. This financing extends XAGE's cash runway into Q1 FY26, supporting its planned merger with 20/20 BioLabs and the ongoing delivery of innovative longevity products. CEO Rajiv Shukla expressed confidence in investor support for the company's vision and growth strategy. The successful fundraising and planned merger with 20/20 BioLabs are significant strategic moves that could enhance XAGE's market position and financial performance.

Longevity Health Holdings, Inc. (XAGE) has announced that it will continue to be listed on Nasdaq as it moves forward with its merger with 20/20 Biolabs. This decision is part of the company's strategic efforts to enhance its market position and operational capabilities in the longevity health sector. The merger with 20/20 Biolabs is a significant strategic move that could enhance Longevity Health's market position and operational capabilities.

Longevity Health Holdings, Inc. (XAGE) announced a merger agreement with 20/20 BioLabs, with 20/20 expected to operate as a subsidiary post-merger. Q1 sales for XAGE reached approximately $663,000, an 8% increase year-over-year, while 20/20 reported $562,000, a 15% increase. A 1 for 30 reverse stock split was completed on May 12, 2025. Upcoming product launches include a medicated cleanser for physicians and MedSpas, and a new lab test for inflammatory biomarkers by 20/20. XAGE is also exploring additional financing options. The merger and new product launches are significant strategic moves that could greatly influence XAGE's market position and financial performance.

Longevity Health Holdings, Inc. (NASDAQ: XAGE) announced a 1-for-30 reverse stock split effective May 12, 2025, following approval from stockholders. The split reduces outstanding shares from approximately 30.1 million to about 1 million, with no fractional shares issued. The company's common stock will begin trading on a split-adjusted basis on May 14, 2025. Adjustments will also be made to stock options and warrants. The transfer agent will manage the exchange process for stockholders. The reverse stock split may moderately influence the company's market perception and stock performance but is not expected to fundamentally alter its business trajectory.

Longevity Health Holdings, Inc. (Nasdaq: XAGE) has announced a merger agreement with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease management. The merger follows Longevity's acquisition of Elevai Skincare and is expected to double its fiscal year 2025 revenue from $3-4 million to $7-8 million. The combined company will continue trading under the symbol 'XAGE' and will be led by a management team from both companies. The merger has been unanimously approved by both boards and is anticipated to close in Q3 2025, pending stockholder approval. The merger is a significant strategic move that is expected to double revenue and enhance the company's market position in diagnostics and healthy aging.

Carmell Corporation has rebranded as Longevity Health Holdings, Inc. to align its image with its focus on longevity and healthy aging. The company's stock will now trade under the symbols 'XAGE' and 'XAGEW'. CEO Rajiv Shukla emphasized the growth strategy, which includes acquisitions and partnerships, alongside organic growth. Following the acquisition of Elevai Skincare, sales increased by 34% in early 2025. The company anticipates FY25 revenues of $3 to $4 million and plans to launch new products in Q2 2025. Patrick Sturgeon has been appointed Vice Chairman. The rebranding and strategic focus on longevity, along with significant product launches and acquisitions, are likely to significantly impact the company's future performance.

Carmell Corporation has successfully completed its acquisition of Elevai Skincare, a move aimed at enhancing its product offerings in the skincare market. This strategic acquisition is expected to bolster Carmell's position in the beauty and wellness sector, aligning with its growth objectives. The acquisition of Elevai Skincare is a significant strategic move that could enhance product offerings and market positioning.

Carmell Corporation (CTCX) closes PIPE investment to support commercial build-out. The significant investment from existing and new investors is expected to have a major impact on Carmell Corporation's future growth and market performance.

Carmell Corporation (CTCX) has signed a definitive agreement to acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products. The acquisition of Elevai Skincare is a significant move that could alter Carmell Corporation's trajectory and market sentiment.

Carmell Corporation announced a private placement of common stock and warrants to raise $1.85 million for commercial build-out of bio-aesthetics product pipeline. The private placement of common stock and warrants is a significant move that could impact Carmell Corporation's future financial performance and product development.

Carmell Corporation partners with Ladies Playbook to provide regenerative skincare products to NFL community. Partnership with Ladies Playbook and focus on expanding direct-to-consumer channels can significantly impact Carmell's growth and market presence.

Carmell Corporation completes post-merger integration with Axolotl Biologix, announces new organizational structure focused on aesthetics. The changes in leadership, board composition, and strategic focus are significant and likely to have a major impact on Carmell Corporation's future trajectory.

Kendra Bracken-Ferguson appointed CEO of Carmell Corporation to lead growth and innovation in skincare and haircare. Appointment of new CEO with extensive industry experience and strategic vision expected to significantly impact company's growth and brand building efforts.

Carmell Corporation closed a $3 million private placement, issuing 1,331,452 shares of common stock. The private placement is expected to moderately influence Carmell's financial performance and product innovation.

Carmell Corporation announced a $3.0 million private placement with new and existing investors for the issuance and sale of common stock. The private placement is a significant move that could impact Carmell Corporation's future financial performance and market positioning.

Carmell Corporation successfully closes sale of Axolotl Biologix to initial sellers for stock and debt cancellation. Sale of AxoBio significantly impacts Carmell's financial position and strategic focus.

Carmell Corporation sells Axolotl Biologix subsidiary to focus on skincare products launch. Sale of subsidiary and focus on skincare products launch expected to significantly impact Carmell's future trajectory and market performance.

Carmell Corporation to host Investor Webinar on Secretome technology for skin and hair health. Significant impact expected on future product launches and market positioning.

Carmell Corporation completes product development for G.L.E.E. launch in March 2024, with 9 other skincare products in the pipeline. Significant impact likely on future and performance due to major product launches and innovative technology developments.

Carmell Corp adds Scott Frisch and Gilles Spenlehauer to Board of Directors. Significant impact likely on future and performance due to addition of experienced industry professionals to the Board.

Axolotl Biologix merges with Carmell Therapeutics, creating a market leader in regenerative medicine. The merger between Axolotl Biologix and Carmell Therapeutics is expected to significantly alter Carmell Corporation's trajectory and competitive positioning.

Carmell Corporation successfully merges with Axolotl Biologix and rebrands as Carmell Corporation. The merger and rebranding are expected to have a significant impact on Carmell Corporation's future growth and market performance.

Carmell Therapeutics merges with Axolotl Biologix, a profitable regenerative medicine company. The merger with Axolotl Biologix is a significant strategic move that is expected to have a major impact on Carmell Corporation's future and market performance.